There is also evidence that pioglitazone is able to reduce levels of pro-inflammatory cytokines, such as resistin [96], which has a significant role in cardiovascular diseases, diabetes and the metabolic syndrome [97]. This evidence concerns the gene RETN and metabolic syndrome.